The biosimilar market was supposed to be simple: copy the molecule, undercut the price, capture the share. Instead, it’s become one of the most complex battlefields in pharma. At Octavus Consulting, we’ve spent the last two years helping clients navigate…

Every company has a “Phase III heartbreak.” The molecule looked perfect—mechanism sound, safety profile strong—but the primary endpoint missed. Most teams bury the data. At Octavus Consulting, we treat it as a gold mine. The Opportunity in Failure Clinical failures…

When Gilead acquired Forty Seven Inc. in 2020, most observers called it quick. Those who tracked macrophage checkpoint research knew it was inevitable. That’s the power of strategic intelligence—not reacting to news, but foreseeing inevitabilities. At Octavus Consulting, we help…

In 2025, Real-World Evidence (RWE) is no longer an afterthought in regulatory filings. It’s a design principle. We recently worked with a biotech firm developing an oncology therapy struggling with limited trial enrollment and payer skepticism. Instead of waiting until…

When a biotech misses its launch date, it’s rarely the science that fails — it’s the supply chain. In one 2024 case, a company developing a monoclonal antibody chose a CDMO solely based on cost per gram. Six months later,…

At Octavus Consulting, we often see pharma teams with all the right data but none of the right speed. They have dashboards, trackers, and CI reports — yet, when a competitor announces trial success or a new filing, the organization…